Kornimate/medical-research-clean huggingface dataset:
melanated group midwifery care (mgmc)

Conditions: Pregnancy Complications; Maternal Care Patterns; Patient Engagement

Summary: this study is being conducted to determine if a multi-level intervention for delivering maternity care can improve patient trust and engagement among black birthing people.

low-risk pregnant participants will be randomized into melanated group midwifery care or usual individualized obstetric care. in melanated group midwifery care (mgmc), black women will receive prenatal care from a black midwife in groups with the same 8-10 other black women throughout pregnancy. in pregnancy and into the first year postpartum, mgmc patients will stay connected to the health system through a proactive care coordinator, who is a black licensed nurse. for the first year after giving birth, patients in mgmc will also be supported by a trained postpartum doula. all participants (intervention and usual care groups) will complete study measures that include validated surveys on patient trust, respect and engagement at 6 time points: * 3 time points in pregnancy \[baseline (\<20 weeks), 26-28 weeks, and 35- 37 weeks\] and * 3 in the postpartum at 2-, 6-, and 12-months * additional qualitative interviews will be done to track the care received by medically and socially complex patients, including all who experience a severe maternal morbidity. the investigators will also document how mgmc gets embedded in practice through a qualitative process evaluation.

Eligibility criteria:
inclusion criteria for patients: * pregnant women who self-identify as black on a standard prenatal intake form * less than 20 weeks pregnant * 15 years old or older * present to the general obstetrics group at the university of chicago medical center for their new prenatal visit * speak and understand english inclusion criteria for providers: • all black midwives, care coordinators, and community postpartum doulas at the university of chicago are eligible to participate. exclusion criteria for patients: * having a condition for which they present to a higher level of obstetrics care (e.g., maternal fetal medicine) for their new prenatal visit * having a cognitive issue that impairs their ability to give informed consent.
a study of the safety and efficacy of venetoclax in japanese participants with relapsed and refractory chronic lymphocytic leukemia (including small lymphocytic leukemia)

Conditions: Cancer; Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Leukemia (SLL)

Summary: this study will collect real-world safety and efficacy data from japanese relapse/refractory chronic lymphocytic leukemia (cll) and small lymphocytic leukemia (sll) participants treated with venetoclax.


Eligibility criteria:
inclusion criteria: -prescribed and treated with venetoclax exclusion criteria: none

Keywords: cancer chronic lymphocytic leukemia (cll) small lymphocytic leukemia (sll) relapsed/refractory venetoclax
effects of acupressure applied to intensive care patients on physiological parameters, pain, sleep quality, anxiety and perception of nursing presence

Conditions: Acupressure; Intensive Care Unit; Anxiety; Nursing Presence; Sleep Quality; Physiological Parameters

Summary: this study will be conducted in a randomized controlled experimental design to examine the effects of acupressure applied to patients treated in the intensive care unit on physiological parameters, pain, sleep quality, anxiety and perception of nurse presence. the study will be conducted with 60 patients (20 intervention, 20 placebo, 20 control groups) treated in the 2nd stage intensive care unit of an university hospital between may 2025 and january 2026. acupressure will be applied to the intervention group for 2 days, morning and evening, for four sessions. for four sessions, pseudo acupressure will be used on the placebo group for 2 days, morning and evening. no application will be made to the control group. the data collection tools in the study are the patient identifier information form, glasgow coma scale (gcs), visual assessment scale (vas), physiological parameter assessment form, richards-campbell sleep scale, spielberg state-trait anxiety inventory, and nurse presence scale (pons).


Eligibility criteria:
inclusion criteria: * have received intensive care treatment for at least 48 hours, * are 18 years of age or older, * have a glasgow coma scale score of \>13, * can speak and write in turkish, * have no psychiatric diagnosis, * have no communication problems, * have a vas score of ≥1, * have a mean arterial pressure of ≥65, * have spo2 of ≥85. exclusion criteria: have previously received acupressure treatment, * have ulcers, necrotic tissue and signs and symptoms of infection at the points where pressure will be applied, * have used antihypertensives, beta-blockers and similar medications, * have sedation, * have respiratory support from the device, * have inotropic treatment (dopamine, steradin and others), * have analgesic treatment in their routine treatment will not be included in the study. patients who were discharged during the study, * patients who died during the study, * patients who wanted to leave the study, * patients who started receiving sedation during the application, * patients who added antihypertensive, beta-blocker and similar drugs to their routine treatment during the application, * patients who received inotropic treatment (dopamine, steradin and others) during the application, * patients who started receiving analgesia treatment during the application, * patients who developed ulcers, necrotic tissue and infection at the points where pressure will be applied during the application, * patients who started receiving respiratory support from the device during the application, * patients who had a glasgow coma scale score of ≤13, mean arterial pressure of ≤65 and spo2 of ≤85 during the application will be excluded from the study.

Keywords: acupressure intensive care unit anxiety nursing presence sleep quality physiological parameters
effects of rhythmic balance auditory vision training and strength training with autism spectrum disorder.

Conditions: Autism Spectrum Disorder

Summary: autism, a complex neurodevelopmental disorder that is marked by limited interests, and challenges in communication and social interactions and problem includes difficulties in understanding and responding to social cues, repetitive behaviors, intense focus on specific interests, and challenges with verbal and nonverbal communication. rhythmic balance auditory vision training (rbavt) a therapeutic approach which helps in improving coordination and balance in individuals with various neurological conditions. strength training enhance physical health and muscle development. thus, the purpose of this study is to compare the effects of rhythmic balance auditory vision training and strength training on motor function and cognition in children with autism spectrum disorder.

this randomized clinical trial will be conducted in autism center lahore. sample of 76 patients will be recruited in this trial by using the convenience sampling technique. participants will be randomly allocated in two groups using lottery method. group a will receive rhythmic balance visual auditory exercise. group b will receive strength training exercises. both groups will receive routine physical therapy as baseline treatment. all the participants will receive 3 sessions per week for 12 weeks.bruininks-oseretsky test of motor proficiency (bot-2) will be used assessment tool to measure fine and gross motor skills and wisconsin card sorting test (wcst) will be assessment tool that evaluates cognitive flexibility and problem-solving abilities.

Eligibility criteria:
inclusion criteria: 1. age range between 6 and 12 years. 2. rating scale (cars) with scores ranging from 30 to 36. 3. confirmation of the diagnosis of autism by a psychiatrist based on diagnostic and statistical manual of mental disorders. 4. physical and cognitive ability exclusion criteria: 1. children with history of auditory, visual, or respiratory deficits, or fixed deformities of the extremities. 2. medical contraindications such as orthopedic or acute conditions that hinder participation in the exercise program. 3. history of psychotropic medication within the last 4 weeks.

Keywords: autism cognition motor function strength training
flupirtine as oral treatment in multiple sclerosis

Conditions: Relapsing Remitting Multiple Sclerosis

Summary: flupirtine, a non-opioid analgesic drug, that has been shown to have additional neuroprotective functions, is given twice daily as an oral medication in patients with relapsing remitting multiple sclerosis over a period of 12 months. neuroprotection is assessed by magnetic resonance imaging, magnetic resonance spectroscopy, optical coherence tomography, and clinical examination.


Eligibility criteria:
inclusion criteria: * relapsing-remitting ms according to the revised mcdonald-criteria (2005) * edss ≤ 4.0 * stable treatment with interferon-β1b for at least 6 months * sufficient birth control (pearl-index \<1) exclusion criteria: * any other ms-course than rrms * clinically relevant gastrointestinal disease * clinically relevant pulmonary, cardiological, infectious or cns-disease * clinically relevant disease of liver or bile system, pathological value for transaminases, gamma-gt or bilirubin. * hepatitis (except uncomplicated hepatitis a with complete remission * clinically relevant dysfunction of kidneys (creatinine \>180 µmol/l) or bone marrow (hb \< 8.5 g/dl, wbc \< 2.5/nl thrombocytes \< 125/nl) * myasthenia gravis * oral anticoagulation (phenprocoumon) * treatment with carbamazepine or paracetamol * drug or alcohol abuse * pregnancy or lactation period * treatment at any time before or during study with complete lymphoradiation, monoclonal antibodies (e.g. anti-cd4, campath 1h, natalizumab), mitoxantrone, cyclophosphamide, cyclosporin, azathioprine * treatment within 6 months before randomization with any other immunomodulatory substance than interferon-β1b or intravenous methylprednisolone
two-dose level evaluation of nx-1207 for the treatment of low risk, localized (t1c) prostate cancer

Conditions: Prostate Cancer

Summary: this study is designed to evaluate the safety and efficacy of a single injection of nx-1207 for the treatment of biopsy-confirmed low risk localized (t1c) prostate cancer in patients currently undergoing active surveillance. study participants currently on active surveillance will be randomized either to treatment with a single intraprostatic injection of nx-1207 (2.5 mg or 15 mg) followed by active surveillance or to no treatment (continued active surveillance). blinded efficacy evaluation will be by a second post-treatment prostate biopsy.


Eligibility criteria:
inclusion criteria: * t1c prostate cancer * gleason score ≤ 6 with no gleason pattern of 4 or 5. * life expectancy ≥ 5 years. * single positive prostate biopsy core with ≤ 50% cancer * psa ≤ 10 ng/ml exclusion criteria: * previous active treatment (such as surgery, brachytherapy, radiotherapy) for prostate cancer. * evidence of metastatic disease or previous positive bone scan. * previous hormonal therapy for prostate cancer. * use of certain concomitant medications, including 5 alpha reductase inhibitors (e.g. finasteride, dutasteride), androgen receptor blockers (e.g. flutamide, bicalutamide), immunosuppressants(such as imuran™, enbrel™, remicade™, humira™, etc.), anticoagulants(such as coumadin™ or heparin), or chemotherapeutics. * previous surgical or invasive prostate treatments such as turp, tumt, tuna, laser or any other minimally invasive treatment within the past 12 months. * pelvic irradiation. * urinary tract infection more than once in the past 12 months. * acute or chronic prostatitis in the past 12 months. * clinically significant renal or hepatic impairment. * bleeding disorder. * poorly controlled diabetes type 1 or type 2. * urinary retention in the previous 12 months. * self-catheterization for urinary retention. * post-void residual urine volume \> 200 ml. * prior significant rectal surgery or any rectal condition with rectal stenosis or fistula. * history of alcohol or substance abuse or dependence within the past 2 years.

Keywords: prostate prostate cancer localized prostate cancer t1c prostate cancer focal therapy nx-1207
a study to evaluate the safety of da-3030 and to explore the efficacy for diabetic neuropathic pain

Conditions: Diabetic Neuropathy

Summary: a multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is designed to evaluate the safety of the da-3030 injection and to explore the efficacy for neuropathic pain.


Eligibility criteria:
inclusion criteria: * 20≤ age ≤ 70 * diagnosed with type i or type ii diabetes * hba1c ≤ 11% * patients with diabetic neuropathic pain for at least 3 months * patients corresponding to average pain level of 4 points or mor for 24 hours evaluated with 11-point likert scale exclusion criteria: * neuropathic pain due to other causes * another stronger pain other than neuropathic pain * abnormality in blood pressure, weight * positive reaction in hiv, hbv or hcv * a medical history of mental illness within 6 months * the grade of bdi(beck depression inventory) exceeds 21 points * history of drug/alcohol abuse
interactive patient's assistant - lucy

Conditions: Chronic Heart Failure

Summary: patients with chronic heart failure (chf) and reduced left ventricle ejection fraction benefit from cardiac resynchronization therapy (crt) and implantable cardioverter defibrillator (icd). currently used devices, besides delivering low and high-energy therapies, record patient's activity and many hemodynamic parameters. however, increasing numbers of patient with crt and icd devices produce overload of cardiology centers where patients are admitted to ambulatory visits. contrarily, there are technological possibilities for remote monitoring proven to be effective in recognizing damage of the implanted device and risk of exacerbation of chronic heart failure. patients' registries show that majority of ambulatory visits are unproductive and do not result in significant modification of device's parameters. promising experiences with application of data mining and machine learning techniques allow us to assume probable benefits from using modern methods of data analysis in determination of requirement for ambulatory follow-up on basis of data gathered through telemonitoring and clinical assessment of a patient. aim of the study is to find multivariate model predicting the requirement for ambulatory follow-up of iecd.


Eligibility criteria:
inclusion criteria: * 18-90 years old * chronic heart failure (nyha class i to iii) * implanted icd or crt (at least 30 days before inclusion)

Keywords: cardiac implantable electronic device cardiac resynchronization therapy implantable cardioverter-defibrillator machine learning mobile application patient's assistance
an observational study to assess quality of life and satisfaction of young women (aged 18-29) following 6 (±1) months using jaydess as their contraceptive method

Conditions: Quality of Life

Summary: this is a cross-sectional, multicenter observational study to assess quality of life in young spanish women (aged 18 to 29) who use jaydess® as their contraceptive method. the study will be conducted in standard clinical practice conditions at the private gynecology clinics and during a single study visit. approximately 1,200 women who have been using the intrauterine delivery system (ius) jaydess® as their contraceptive method of choice for 6 (±1) months will be included in the study.


Eligibility criteria:
inclusion criteria: * women aged 18 to 29 years. * women who have been using jaydess as their contraceptive method for 6 (±1) months. * women who have no comprehension, reading or writing challenges. * women who have given informed consent in writing. exclusion criteria: * contraindication to the use of jaydess. * prescription of jaydess® for non-contraceptive medical reasons. * women who are considered to be unsuitable to take part in the study by the investigator (e.g., poor understanding of the study characteristics, uncooperative, etc.). * women who are currently taking part in any clinical trial.
is there a relationship between stress tolerance and analgesic consumption in obese patients?

Conditions: Distress Tolerance

Summary: preoperative anxiety level of patients affects postoperative analgesic consumption. however, there were no studies that showed a relationship between the level of stress tolerance and analgesic consumption in the literature. in this study, investigators wanted to investigate the effect of stress tolerance on analgesic consumption of patient.

after approval, patients enrolled in the study is invited to complete the pain catastrophizing scale questionnaire, distress tolerance scale and beck anxiety scale.after surgery, vas scores of the patients will be evaluated (in the recovery room, 2,6,12 and 24 hours). and patients with vas\> 3 will receive 2 mg of morphine.the relationship between total analgesic consumption and the stress tolerance will be evaluated.the study will be performed with 69 sleeve gastrectomy patients(bmi\>30).

Eligibility criteria:
inclusion criteria: * between 18 and 60 years * planned to sleeve gastrectomy * an american society of anesthesiologists score of 1 or 2 bmi\>30 exclusion criteria: * psychiatric diseases * rejected to participation
study of low-intensity focused ultrasound effects on heat evoked fmri signals

Conditions: Pain

Summary: study aims to examine the effects of noninvasive brain stimulation on brain signals. this insight may have potential clinical implications for addiction, pain, and mental health populations. participants will receive mri and ct imaging. participants receive low-intensity focused ultrasound (lifu) to temporarily change brain activity. participants then receive fmri scans to measure changes in both resting and heat evoked brain signaling using a quantitative sensory testing device. heart rate, blood pressure, respiratory rate, and skin moisture is monitored. participants complete a battery of questionnaires, both behavioral and symptom monitoring. the study takes place over 4 study visits.


Eligibility criteria:
inclusion criteria: * healthy volunteers, all ethnicities, who understand and speak english. exclusion criteria: claustrophobia (scanning environment may be uncomfortable). contraindications to mri: including pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants. contraindications to ct: pregnancy active medical disorder or treatment with potential cns effects (e.g. alzheimer's) history of neurologic disorder. (e.g. parkinson's, epilepsy, or essential tremor) history of head injury resulting in loss of consciousness for \>10 minutes. history of alcohol or drug dependence (through self-report).
host dna methylation for endometrial cancer screening

Conditions: Cancer Screening; Endometrial Cancer; DNA Methylation; Cervical Cytology; Liquid Biopsy; Cohort Study

Summary: based on the previous study of nct04651738, we performed this trial to further confirm the accuracy of host dna cdo1 and celf4 methylation for endometrial cancer screening in a multi-center cohort. thirteen hospitals, including peking union medical college hospital, would enroll eligible patients in this study. the cervical cytology of 3 ml will be collected for the detection of dna cdo1 and celf4 methylation, and the results will compared with the endometrial histological pathology, which is achieved after collection of cervical cytology, by surgeries including hysteroscopy, dilation and curettage, total hysterectomy and others. the methylation testing would be double-blinded in operators and analysts. the study will enroll at least 10,000 patients.


Eligibility criteria:
inclusion criteria: * with uterine and uterine cervix intact * aged 18 years or older * with accessible histological results of endometrium * signed an approved informed consents * with accessible cervical cytology before harvesting endometrial histology exclusion criteria: * not meeting all of the inclusion criteria
influence of severe heart failure to function and molecular biological parameters of catabolism in the human diaphragm and peripheral skeletal muscle

Conditions: Heart Failure; Ischemic Myocardiopathy; Dilatative Myocardiopathy

Summary: project aim is to quantify the influence of a severe therapy-refractory heart failure caused by ischemic or dilative myocardiopathy on the function of the diaphragm, its molecular biological parameters and on the m. vastus lateralis. the control group consists of patients with coronary artery disease (cad) and normal left ventricular ejection fraction indicated for coronary artery bypass graft surgery (cabg) differences in the geneses of heart failure (ischemic vs. dilative cardiomyopathy) will be evaluated during analysis. the ubiquitin-proteasome signaling pathway is considered as a central issue for the mechanism of the analyses muscle catabolism.


Eligibility criteria:
inclusion criteria: inclusion criteria group a: * age 40 - 70 years * restricted left ventricular pump function left ventricular ejection fraction (lvef) \> 35% on the basis of ischemic cardiomyopathy (icm) and restricted resting cardiac output (ci\> 2.4 l / min / m²) * or restricted maximal oxygen uptake (vo2max\> 17 ml / min / m²) * duration of heart failure\> 1 year * maximum of individual heart failure therapy * heart team decision to lvad implantation inclusion criteria group b: * age 40 - 70 years * restricted left ventricular pump function (lvef) \> 35% on the basis of dilatative cardiomyopathy (dcm) and restricted resting cardiac output (ci\> 2.4 l / min / m²) * or restricted maximal oxygen uptake (vo2max\> 17 ml / min / m²) * duration of heart failure\> 1 year * maximum of individual heart failure therapy * heart team decision to lvad implantation inclusion criteria group c: * age 40 - 70 years * coronary heart disease with indication for elective, coronary artery bypass surgery * normal left ventricle (lv) pumping function lvef\> 50% * stable clinical situation (no cardiac decompensation within the last 6 months) exclusion criteria: * mechanical ventilation within the last 3 months * forced expiratory pressure (fev1) \<70% of the norm and / or therapy with α antagonists, β-mimetics or inhaled corticosteroids for the treatment of a lung disease * pulmonary fibrosis * elevated diaphragm in the ultrasound or x-ray diagnosis or known paresis of the phrenic nerve * chronic kidney disease (ckd) stage 4 and 5, i.e. glomerular filtration rate (gfr) \<30ml / min / 1.73m and / or dialysis * acute renal failure * treatment with immunosuppressive agents * hepatic insufficiency child-pugh b and c * higher grade ventricular arrhythmias (lown iv b) * acute myocardial infarction (less than three months) * decompensated vitium cordis * age \ 70 years * pregnancy